Germany has become one of the fastest-growing legal cannabis markets since enacting the Cannabis Act (CanG) in April 2024. The German medical cannabis segment has experienced significant growth due to eased access conditions following cannabis’s delisting from the narcotics list. Telemedicine platforms have also driven value growth by expanding patient reach, particularly in remote areas.
The rise of telemedicine in cannabis is a double-edged sword. While it democratises access, it may lead to quasi-recreational consumption and increased regulatory scrutiny. Other markets, such as Poland, Brazil, and Australia, have also seen a surge in digital platforms for medical cannabis. On the one hand, Poland's tightening of telemedicine rules led to an initial sales drop, but sales rebounded months later. On the other, Australia's regulatory agency has emphasised the importance of telehealth consultations.
Germany is considering telemedicine restrictions similar to Poland's. The impact of such restrictions remains to be seen, but Poland's experience suggests that the industry can adapt.
For more insights and regulatory updates on the cannabis industry, explore our Cannabis system for the latest data and content.